Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Biotech Industry Analysis

UpdatedMar 15, 2026
DataAggregated Company Financials
Companies5
  • 7D0.5%
  • 3M-20.2%
  • 1Y-2.7%
  • YTD-19.4%

The Biotech is pretty flat in the last 7 days, but Zealand Pharma has stood out, gaining 14%. In line with that, the industry has also been flat over the past 12 months. As for the next few years, earnings are expected to grow by 2.8% per annum.

Industry Valuation and Performance

Has the Danish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 15 Mar 2026DKK 138.2bDKK 39.8bDKK 14.0b10.2x9.8x3.5x
Tue, 10 Feb 2026DKK 163.7bDKK 40.2bDKK 18.8b6.1x8.7x4.1x
Thu, 08 Jan 2026DKK 179.5bDKK 40.7bDKK 19.0b6.4x9.4x4.4x
Sat, 06 Dec 2025DKK 176.4bDKK 40.8bDKK 19.1b6.1x9.3x4.3x
Mon, 03 Nov 2025DKK 168.5bDKK 39.2bDKK 16.9b12.7x10x4.3x
Wed, 01 Oct 2025DKK 169.6bDKK 38.8bDKK 16.7b12.6x10.1x4.4x
Fri, 29 Aug 2025DKK 149.3bDKK 38.9bDKK 16.8b11.3x8.9x3.8x
Sun, 27 Jul 2025DKK 137.1bDKK 26.9bDKK 7.3b13.2x18.8x5.1x
Tue, 24 Jun 2025DKK 123.3bDKK 27.1bDKK 7.4b10.7x16.7x4.5x
Thu, 22 May 2025DKK 129.4bDKK 28.0bDKK 7.9b10.5x16.4x4.6x
Sat, 19 Apr 2025DKK 124.4bDKK 27.3bDKK 7.7b11.2x16.2x4.6x
Mon, 17 Mar 2025DKK 144.9bDKK 27.3bDKK 7.7b12.3x18.9x5.3x
Wed, 12 Feb 2025DKK 152.2bDKK 26.0bDKK 4.7b15.3x32.4x5.8x
Fri, 10 Jan 2025DKK 170.6bDKK 26.0bDKK 4.7b18x36.3x6.6x
Sun, 08 Dec 2024DKK 173.1bDKK 26.0bDKK 4.7b17.8x36.9x6.6x
Tue, 05 Nov 2024DKK 176.2bDKK 25.5bDKK 5.5b20.8x32.2x6.9x
Thu, 03 Oct 2024DKK 178.4bDKK 25.5bDKK 5.5b21.6x32.6x7x
Sat, 31 Aug 2024DKK 203.5bDKK 25.5bDKK 5.5b25.4x37.2x8x
Mon, 29 Jul 2024DKK 201.2bDKK 24.8bDKK 5.6b18.4x35.7x8.1x
Wed, 26 Jun 2024DKK 182.9bDKK 24.8bDKK 5.6b16.6x32.5x7.4x
Fri, 24 May 2024DKK 182.8bDKK 24.8bDKK 5.6b19x32.5x7.4x
Sun, 21 Apr 2024DKK 178.7bDKK 23.9bDKK 5.0b18.9x35.5x7.5x
Tue, 19 Mar 2024DKK 189.6bDKK 23.9bDKK 5.0b19.5x37.7x7.9x
Thu, 15 Feb 2024DKK 165.3bDKK 23.3bDKK 4.2b22.7x39.7x7.1x
Sat, 13 Jan 2024DKK 182.0bDKK 23.3bDKK 4.2b25.5x43.7x7.8x
Mon, 11 Dec 2023DKK 182.3bDKK 23.3bDKK 4.2b26.3x43.8x7.8x
Wed, 08 Nov 2023DKK 160.7bDKK 22.0bDKK 4.7b18.9x33.9x7.3x
Fri, 06 Oct 2023DKK 189.6bDKK 22.0bDKK 4.7b22.4x40x8.6x
Sun, 03 Sep 2023DKK 200.9bDKK 22.0bDKK 4.7b23.8x42.5x9.1x
Tue, 01 Aug 2023DKK 207.5bDKK 19.5bDKK 4.4b36x47.1x10.6x
Thu, 29 Jun 2023DKK 196.5bDKK 19.5bDKK 4.4b41x44.6x10.1x
Sat, 27 May 2023DKK 214.9bDKK 19.5bDKK 4.4b42.1x48.8x11x
Mon, 24 Apr 2023DKK 210.8bDKK 17.9bDKK 3.5b32.9x59.6x11.8x
Wed, 22 Mar 2023DKK 192.6bDKK 17.9bDKK 3.5b30.1x54.3x10.8x
Price to Earnings Ratio

54.3x


Total Market Cap: DKK 192.6bTotal Earnings: DKK 3.5bTotal Revenue: DKK 17.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Biotech Industry Price to Earnings3Y Average 30.3x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 9.8x which is lower than its 3-year average PE of 30.3x.
  • The 3-year average PS ratio of 6.9x is higher than the industry's current PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have grown 58% per year over the last three years.
  • Revenues for these companies have grown 31% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare industry?

DK Market-1.27%
Healthcare-0.76%
Biotech0.48%
Biotech0.48%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ZEAL Zealand PharmaDKK 268.2014.2%
+DKK 2.4b		-54.2%PE2.9x
STRAP Strategic PartnersDKK 642.0010.7%
+DKK 2.6m		-9.7%PB1.5x

Latest News

BAVA
DKK 181.55
Bavarian Nordic
7D
-0.6%
1Y
8.5%
ZEAL
DKK 268.20
Zealand Pharma
7D
14.2%
1Y
-54.2%

ZEAL: Petrelintide Obesity Data And Pipeline Progress Will Support Future Upside

The updated analyst price target for Zealand Pharma moves lower to DKK 611 from about DKK 730, as analysts factor in reduced expectations for petrelintide's obesity opportunity, modestly higher risk assumptions, and a lower implied future P/E multiple, following a series of rating downgrades to Neutral or Hold. Analyst Commentary Recent research notes cluster around a more cautious stance on Zealand Pharma, with several firms shifting ratings to Neutral or Hold and setting price targets below the prior DKK 730 level.
GMAB
DKK 1,702.50
Genmab
7D
-1.5%
1Y
20.4%

GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook

Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.
BIOPOR
DKK 0.90
BioPorto
7D
-1.6%
1Y
-38.9%
STRAP
DKK 642.00
Strategic Partners
7D
10.7%
1Y
-9.7%